Navigation Links
Penn receives $10 million to create center for orphan disease research and therapy

PHILADELPHIA - The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania announces the launching of a first-of-its-kind interdisciplinary center focused on discovering novel treatments for orphan diseases. The Center will bring together, without institutional walls, all necessary approaches to attacking and treating orphan diseases: establishing dedicated research support facilities, translating findings into therapies, fostering targeted grant awards, and educating physicians and researchers.

Formation of the new Penn Center for Orphan Disease Research and Therapy was catalyzed by a $10 million gift from an anonymous donor, whose vision matched that of Penn Medicine in developing treatments for these diseases. The Center will fill a crucial need by providing the core laboratories, techniques, collaborative relationships, and expertise to lead an international, coordinated effort in the eradication of orphan diseases. Key among these resources is a state-of-the-art, robotically controlled drug screening laboratory that enables researchers from around the world to rapidly probe existing compound libraries for effective, orphan disease treatments.

Diseases are classified as orphan when they affect fewer than 200,000 people. However, as there are approximately 7,000 diseases now identified in this population, more than 25 million Americans are currently afflicted. Many of these diseases are caused by genetic mutations and are diagnosed in children. Research in many orphan diseases has lagged behind other major disease categories, such as diabetes and cardiovascular disease, in part because of a relative lack of technical expertise and funding mechanisms. Penn's Center will specifically address these needs.

"The research and development marketplace is not designed to optimally support research to develop the therapies so desperately needed for orphan diseases," explains Glen N. Gaulton, Ph.D., Executive Vice Dean and Chief Scientific Officer at the Perelman School. "Penn's new Center for Orphan Disease Research and Therapy will build not only strong collaborative relationships throughout Penn, but also with other leading academic medical centers, as well as public and private institutionsall designed to translate innovative research into the clinic. There's simply nothing else like it."

"This is a wonderful example of philanthropy in action," says J. Larry Jameson, M.D., Executive Vice President for the Health System and Dean of the Perelman School of Medicine. "The Center will be a natural extension of Penn's expertise in orphan diseases, and this strategic investment will galvanize support for orphan disease research around the globe. I am proud that Penn Medicine is taking a clear leadership position in transforming the health of millions."

Jameson adds that he is delighted that his predecessor, former Perelman School Dean Arthur H. Rubenstein, MBBCh, has agreed to serve as Acting Director for the Center, while an international search is conducted for a permanent director.

The Center will be a nexus for connecting:

  • Researchers and clinicians at Penn with other public and private institutions to work on projects aimed at finding and testing treatments for orphan diseases;
  • Approaches to treatment that are common among various orphan diseases;
  • Researchers with organizations that fund biomedical research for orphan diseases; and
  • Investigators within small and large pharmaceutical firms to develop and test treatments for orphan diseases.

Working together with other academic institutions, the National Institutes of Health, Pharma, and private philanthropy, the Center aims to reduce dramatically the technological and financial burden of investigators working in isolation by supporting a range of collaborative approaches:

  • Robotics for large-scale drug screening,
  • Biospecimen repositories to store samples,
  • Genotyping and bioinformatics services to identify causative genes,
  • Cell-based systems for developing new tests,
  • Nano-scale systems for developing new ways to deliver drugs, and
  • Small and large animal models for testing potential treatments.


Contact: Karen Kreeger
University of Pennsylvania School of Medicine

Related medicine news :

1. NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education
2. Dr Yaghouti of Global Laser Vision Receives Patient's Choice Award for 2009
3. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
4. Receives Award for Customer Trust
5. Corporate Wellness Firm Limeade Receives SAS 70 Type II Report
6. Oridion Receives Frost & Sullivan's 2010 Customer Value Enhancement Award
7. Special Olympics Georgia Receives Grant from The Home Depot Foundation
8. NOVAVAX, Inc. Receives NASDAQ Non-Compliance Letter
9. WuXi PharmaTech Receives AAALAC Accreditation for Suzhou Toxicology Facility
10. Verdan Receives Patent on Crystal Deodorant Spray
11. Thomas E. Mower Meets With Dalai Lama; Receives Prestigious Champion Award from Whole Child International
Post Your Comments:
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... UT (PRWEB) , ... November 24, 2015 , ... It ... Magazine. For a business, it is critical that the first impression be positive and ... they are not likely to buy anything or want to return. They will also ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Aided by ... today announced an innovative study designed to yield insights into how to detect and ... of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore is ... certification. The award recognizes good companies for excellence in service and a commitment ... and hard surface restoration company earned this recognition after a thorough review by ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology: